NM_002467.6:c.314G>A (p.Gly105Asp) is absent from all population databases including gnomAD v2.1, v4.1, and gnomAD-Canada v1.0, meeting PM2 at the supporting level.¹ Multiple in silico tools predict no significant impact: REVEL score 0.202 (below pathogenicity threshold), BayesDel score -0.0945 (predicts benign), and SpliceAI max delta 0.01 (no splicing impact), meeting BP4 at the supporting level.² The variant has been reported in somatic cancers (COSMIC COSV52367541, n=5) but without variant-specific functional characterization. No variant-specific functional studies, de novo reports, case-control data, cosegregation data, or ClinVar classifications are available for this variant.³ Under generic ACMG/AMP 2015 combination rules, PM2_Supporting and BP4_Supporting offset each other, yielding no net evidence toward pathogenicity or benignity. The variant is classified as a Variant of Uncertain Significance (VUS).⁴